Expert discusses important FDA approvals for acute myeloid leukemia
Healio spoke with Jonathan M. Gerber, MD, chief of hematology-oncology and medical director of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, Eleanor Eustis Farrington Chair in Cancer Research and HemOnc Today Editorial Board member, about FDA approvals for acute myeloid leukemia, the transition of newer agents into clinical practice, the “underrecognized” burden of high treatment costs, clinical implications of the BEAT-AML trial and breakthroughs in therapy that he hopes to see in the future in this video series.
Watch the video for more on important FDA approvals and exciting treatments for AML.
Click here to watch the next video in the series on using older and newer agents in clinical practice.
Collapse
Read more about